aTyr Pharma, Inc.
ATYR
$3.99
$0.4412.39%
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 5.97% | 4.56% | |||
| Gross Profit | -5.97% | -6.43% | |||
| SG&A Expenses | -0.18% | -4.70% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.78% | 2.63% | |||
| Operating Income | -4.78% | -4.08% | |||
| Income Before Tax | -5.86% | -5.29% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -5.86% | -5.29% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -5.84% | -5.26% | |||
| EBIT | -4.78% | -4.08% | |||
| EBITDA | -4.83% | -4.13% | |||
| EPS Basic | -0.93% | 3.75% | |||
| Normalized Basic EPS | -0.92% | 3.75% | |||
| EPS Diluted | -0.93% | 3.75% | |||
| Normalized Diluted EPS | -0.92% | 3.75% | |||
| Average Basic Shares Outstanding | 4.87% | 9.39% | |||
| Average Diluted Shares Outstanding | 4.87% | 9.39% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
